Daniel N. Streblow, Ph.D.
- Associate Professor, VGTI-Vaccine and Gene Therapy Institute
- Molecular Microbiology and Immunology Graduate Program, School of Medicine
- Program in Molecular and Cellular Biosciences, School of Medicine
Biography
Dr. Daniel Streblow received his B.S. in Pharmacology/Toxicology from the University of Wisconsin-Madison in 1992. He graduated from University of Wisconsin-Madison with a Ph.D. in Viral Pathogenesis in 1997. Dr. Streblow received a NIH post-doctoral fellowship and worked with Dr. Jay A. Nelson in the Department of Molecular Microbiology and Immunology at Oregon Health & Science University. He is currently an Associate Scientist at the Vaccine and Gene Therapy Institute and Research Assistant Professor at the Department of Molecular Microbiology and Immunology.
The focus of the Streblow laboratory is on defining the role of human cytomegalovirus (HCMV) in the development of vascular disease and chronic rejection of organ allografts. The role of CMV in these diseases is still uncharacterized. Dr. Streblow's lab studies the following topics: 1) Determining the mechanisms of HCMV-accelerated vascular disease through identification of the viral genes expressed during these diseases using a HCMV microarray chip developed by Dr. Streblow's laboratory in combination with the Shared Microarray Core at VGTI. Once identified, the function of these viral genes will be examined using in vitro and in vivo models of CMV-accelerated vascular disease. 2) Determining the mechanisms of CMV-accelerated vascular disease in both mouse models of atherosclerosis and rat organ transplantation models using a DNA microarray approach. The Streblow lab in conjunction with Dr. Susan Orloff’s laboratory at OHSU has determined RCMV in vivo gene expression in infected rats and has begun functional studies of these genes. 3) Determine viral and host gene expression during the development of atherosclerosis and transplant vascular sclerosis, the vascular lesion associated with chronic allograft rejection 4) determining the mechanisms of viral acceleration of chronic allograft rejection from latently infected donor, which is the most common cause of HCMV-associated disease in transplant patients associated with expression during the different stages of viremia associated with CMV including 5) Determining the function of CMV-encoded chemokine receptors in the context of viral pathogenesis and acceleration of vascular disease. Dr. Streblow's lab has also generated a rhesus macaque (RM) chikungunya virus (CHIKV) infection animal model to identify correlates of CHIKV pathogenesis and to test novel antivirals and vaccines. They are working on developing a Zika virus RM model.
Education and training
-
Degrees
- B.S., 1992, University of Wisconsin
- Ph.D., 1997, University of Wisconsin
Areas of interest
- CMV pathogenesis and transplantation
Publications
Selected publications
- Hirsch AJ, Smith JL, Haese NN, Broeckel RM, Parkins CJ,Kreklywich C, DeFilippis VR, Denton M, Smith PP, Messer WB, Colgin LM, DucoreRM, Grigsby PL, Hennebold JD, Swanson T, Legasse AW, Axthelm MK, MacAllister R,Wiley CA, Nelson JA, Streblow DN. Zika Virus infection of rhesus macaques leadsto viral persistence in multiple tissues. PLoS Pathog. 2017 Mar9;13(3):e1006219. doi: 10.1371/journal.ppat.1006219. [PMID: 28278237]
- Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE,Streblow DN. Animal Models of Chikungunya Virus Infection and Disease. J InfectDis. 2016 Dec 15;214(suppl 5):S482-S487. [PMID: 27920178]
- Burwitz BJ, Malouli D, Bimber BN, Reed JS, Ventura AB,Hancock MH, Uebelhoer LS, Bhusari A, Hammond KB, Espinosa Trethewy RG, Klug A,Legasse AW, Axthelm MK, Nelson JA, Park BS, Streblow DN, Hansen SG, Picker LJ,Früh K, Sacha JB. Cross-Species Rhesus Cytomegalovirus Infection of CynomolgusMacaques. PLoS Pathog. 2016 Nov 9;12(11):e1006014. doi:10.1371/journal.ppat.1006014.[PMID: 27829026]
- Caviness K, Bughio F, Crawford LB, Streblow DN, Nelson JA,Caposio P, Goodrum F. Complex Interplay of the UL136 Isoforms BalancesCytomegalovirus Replication and Latency. MBio. 2016 Mar 1;7(2):e01986. doi:10.1128/mBio.01986-15.[PMID: 26933055]
Publications
Rhesus Cytomegalovirus-encoded Fcγ-binding glycoproteins facilitate viral evasion from IgG-mediated humoral immunity
Nature communicationsThird intracellular loop of HCMV US28 is necessary for signaling and viral reactivation
Journal of virology4-Substituted-2-Thiazole Amides as Viral Replication Inhibitors of Alphaviruses
Journal of Medicinal ChemistryChikungunya Virus Vaccines
BioDrugsIdentification of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach
Proceedings of the National Academy of Sciences of the United States of AmericaNonreciprocity in CHIKV and MAYV Vaccine-Elicited Protection
VaccinesThe Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
VaccinesAerosol delivery of SARS-CoV-2 human monoclonal antibodies in macaques limits viral replication and lung pathology
Nature communicationsInfection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein
PLoS neglected tropical diseasesIsolation and genome sequencing of cytomegaloviruses from Natal multimammate mice (Mastomys natalensis)
Journal of General VirologyMayaro virus pathogenesis and immunity in rhesus macaques
PLoS neglected tropical diseasesProximity-dependent mapping of the HCMV US28 interactome identifies RhoGEF signaling as a requirement for efficient viral reactivation
PLoS pathogensCommunity-Based SARS-CoV-2 Testing Using Saliva or Nasopharyngeal Swabs to Compare the Performance of Weekly COVID-19 Screening to Wastewater SARS-CoV-2 Signals
ACS ES and T WaterDevelopment of a next-generation chikungunya virus vaccine based on the HydroVax platform
PLoS pathogensTherapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease
Antiviral ResearchBlocking the IL-1 receptor reduces cardiac transplant ischemia and reperfusion injury and mitigates CMV-accelerated chronic rejection
American Journal of TransplantationCD341 hematopoietic progenitor cell subsets exhibit differential ability to maintain human cytomegalovirus latency and persistence
Journal of virologyComparison of SARS-CoV-2 PCR-Based Detection Using Saliva or Nasopharyngeal Swab Specimens in Asymptomatic Populations
Microbiology SpectrumCytomegaloviral determinants of CD8+T cell programming and RhCMV/SIV vaccine efficacy
Science ImmunologyDifferential Type 1 IFN Gene Expression in CD14+ Placenta Cells Elicited by Zika Virus Infection During Pregnancy
Frontiers in VirologyEstablishment of Monoclonal Antibody Standards for Quantitative Serological Diagnosis of SARS-CoV-2 in Low-Incidence Settings
Open Forum Infectious DiseasesFetal Central Nervous System Derived Extracellular Vesicles
Frontiers in VirologyIdentification of quinolinones as antivirals against venezuelan equine Encephalitis virus
Antimicrobial agents and chemotherapyMacrophage depletion of CMV latently infected donor hearts ameliorates recipient accelerated chronic rejection
Transplant Infectious Disease